The Pharmacy Times® Chronic Kidney Disease Resource Center is a comprehensive resource for clinical news and expert insights on issues related to long-term disease of the kidneys leading to renal failure.
March 5th 2024
In the study, investigators found superior kidney outcomes with injectable semaglutide (Ozempic) for individuals with type 2 diabetes and chronic kidney disease.
Risks and Liabilities in Pharmacy Practice
1.0 Credit / Law
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Advances in the Treatment of Metastatic Renal Cell Carcinoma: New Horizons in Targeted Therapies
1.0 Credit / Genitourinary Cancer, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Eleven Potentially Practice-Changing Drugs Were Approved by the FDA in 2023
These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.
Read More
FDA Approves Defencath for Catheter-Related Infections for Those With Kidney Failure
November 15th 2023Taurolidine and heparin (Defencath; CorMedix) is indicated to reduce catheter-related bloodstream infections for adults with kidney failure who are receiving chronic hemodialysis via central venous catheter
Read More
Disproportionate Burden of Cardiovascular-Kidney-Metabolic Factors in Patients with Adverse SDOH
November 15th 2023Session speaker Powell-Wiley explains how screening for SDOH in patients as cardiovascular-kidney-metabolic syndrome stages progress can help better understand their individual social needs.
Read More
IVIG-Based Treatment Increased Survival Rates of Renal Transplantation, Stabilizing Graft Function
August 2nd 2023With an intravenous immunoglobulin-based treatment protocol, individuals who underwent renal transplantation and who were presensitized achieved intermediate-term graft and recipient survival results at 98%.
Read More